The decrease in breast-cancer incidence in 2003 in the United States

New England Journal of Medicine

Volumn 356, Issue 16, 2007, Pages 1670-1674

  Ravdin, Peter M ^a   Cronin, Kathleen A ^b   Howlader, Nadia ^b   Berg, Christine D ^b   Chlebowski, Rowan T ^c   Feuer, Eric J ^b   Edwards, Brenda K ^b   Berry, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; TAMOXIFEN; VITAMIN D; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; ENVIRONMENTAL EXPOSURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MAMMOGRAPHY; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; VITAMIN SUPPLEMENTATION; AGE DISTRIBUTION; AGED; BREAST TUMOR; ESTROGEN THERAPY; FEMALE; HISTORY; INCIDENCE; MIDDLE AGED; REGRESSION ANALYSIS; UNITED STATES; UTILIZATION REVIEW;

AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; SEER PROGRAM; UNITED STATES;

EID: 34247241630     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsr070105     Document Type: Letter

References (17)

1. Ravdin PM, Cronin KA, Howlander N, Chlebowski RT, Berry DA. A sharp decrease in breast cancer incidence in the United States in 2003. Breast Cancer Res Treat 2006;100:Suppl:S2. abstract.
2. Howe HL, Wu X, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711-42.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
4. Buist DSM, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-50.
5. Hersh AL, Stefanick ML, Stafford RS. National use of post-menopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
6. Health, United States 2006, with chartbook on trends in the health of Americans. Hyattsville, MD: National Center for Health Statistics, November 2006:313-4. (DHHS publication no. 2006-1232.)
7. Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999;91:2020-8.
8. Powles TJ, Hickish T. Breast cancer response to hormone replacement therapy withdrawal. Lancet 1995;345:1442.
9. Prasad R, Boland GP, Cramer A, Anderson E, Knox WF, Bundred NJ. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer 2003;98:2539-46.
10. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59. [Erratum, Lancet 1997;350:1484.]
12. Drug Topics. Drugs by units in the United States in specific years. (Accessed March 29, 2007, at http://www.drugtopics.com/drugtopics/.)
13. Freedman AN, Graubard BI, McCaskill-Stevens W, Gail MH, Ballard-Barbash R. Tamoxifen use for breast cancer chemoprevention among U.S. women. Eur J Cancer Suppl 2004;2:17-8.
14. Clarke CA, Glaser SL, Uratsu SL, Selby JV, Kushi LH, Herrington LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24:49e-50e.
15. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
17. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92.